00:00 / 00:00
Endocrine system
Autoimmune polyglandular syndrome type 1 (NORD)
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Diabetes insipidus and SIADH: Pathology review
Diabetes mellitus: Pathology review
Hyperthyroidism: Pathology review
Hypopituitarism: Pathology review
Hypothyroidism: Pathology review
Multiple endocrine neoplasia: Pathology review
Neuroendocrine tumors of the gastrointestinal system: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Pituitary tumors: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Carcinoid syndrome
0 / 18 complete
of complete
2022
2021
2020
2019
2018
2017
2016
bronchial carcinoid tumors p. 707
somatostatin for p. 362
treatment p. 725
carcinoid syndrome p. 357
in carcinoid syndrome p. 357
carcinoid syndrome p. 592
carcinoid syndrome p. 359
for carcinoid syndrome p. 725
carcinoid syndrome p. 359
carcinoid syndrome p. 592
in carcinoid syndrome p. 356
carcinoid syndrome as cause p. 359
Carcinoid syndrome refers to a constellation of symptoms like diarrhea, shortness of breath and flushing, which arise when a specific type of tumor called a neuroendocrine tumor begins secreting hormones.
Neuroendocrine tumors were also called “carcinoid tumors” in the past, because of their association with carcinoid syndrome.
Neuroendocrine cells are found in tissues throughout the body, particularly in the epithelial layer of gastrointestinal organs and the lungs. They receive signals from nerve cells and, in response, they release hormones into the blood.
Neuroendocrine cells release a variety of hormones including amines, like serotonin and histamine; polypeptides, like bradykinin, a vasodilator; and prostaglandins which are also powerful vasodilators. The production of these hormones can also be regulated by other hormones.
For example, somatostatin is a hormone that’s made by cells in the hypothalamus as well as the gastrointestinal tract, and it travels through the blood and binds to receptors on the surface of neuroendocrine cells.
Binding of somatostatin inhibits the release of a number of hormones from neuroendocrine cells, including serotonin.
Now, when serotonin does get released from neuroendocrine cells, it enters the liver through the portal vein.
In the liver, some of the serotonin is metabolized to 5-hydroxyindoleacetic acid which is eliminated from the body through the urine.
The remaining serotonin is not metabolized, and this portion remains in the systemic circulation where it has various effects.
In the gastrointestinal tract, serotonin increases motility and peristalsis; in the vasculature, platelets take up the serotonin and later use it to constrict blood vessels, particularly after injury; and in the connective tissue of the heart, it stimulates fibroblasts which make lots of collagen.
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.